Sperling Awarded $100,000 Prize for Alzheimer’s Research
Reisa A. Sperling, MD, director of the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital and Mass. General Hospital, has received the 2015 Potamkin Prize of $100,000 for Research in Pick’s, Alzheimer’s, and Related Diseases from the American Academy of Neurology and the American Brain Foundation. This prize also honors Peter Davis, PhD, of the Feinstein Institute for Medical Research in Rye, N.Y. The Potamkin Prize honors both Sperling and Davis for their work in helping to advance the understanding of Alzheimer’s. The prize is an internationally recognized tribute for advancing dementia research, and is considered the highest honor in the Alzheimer’s field. Read more.
Groundbreaking Alzheimer’s Trial Featured on CBS News
CBS News interviewed a patient who is participating in a groundbreaking international clinical trial that is the first to examine early treatment of older adults at risk for Alzheimer’s disease – with the hope of preventing memory loss before it begins. Led by Dr. Reisa Sperling, Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study is for people without symptoms, but whose brain scans show the buildup of amyloid plaques. The A4 study is currently enrolling 1,000 participants at 60 sites in the United States, Canada, and Australia. To learn more about the A4 study and other studies for Alzheimer’s disease, please contact the BWH Center for Alzheimer Research and Treatment. Read more.
BWH Designated as Primary Stroke Service Hospital
Brigham and Women's Hospital was recently designated as a Primary Stroke Service by the Massachusetts Department of Public Health - an important distinction that holds BWH to strict regulations established by the DPH to help ensure patients can receive appropriate and timely acute stroke care. Designated hospitals must assure that emergency diagnostic and therapeutic services are provided by a multidisciplinary team and available 24 hours a day, seven days a week to patients presenting with symptoms of acute stroke.
This page was last modified on 9/18/2015